Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

As our digital focus continues, Daniel Ghinn explores the growing anticipation around Boehringer Ingelheim’s launch of Syrum – the first pharmaceutical social game – ahead of its beta launch ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...